Israel Active

Israel’s Theranica (see previously) has reported successful long-term use of its Nerivio Remote Electrical Neuromodulation (REN) device for 409 migraine sufferers in the US. It consistently gave pain relief, functional disability relief and freedom.

Israel’s Magenta Medical (see previously) reported positive results in a 15-patient trial of its Elevate System. The percutaneous Left Ventricular Assist Device (pLVAD) supports circulation in high-risk percutaneous coronary interventions (HR-PCI).

Israel’s Can-Fite (see previously) is developing small molecule medicines that address oncology and inflammatory diseases. It has partnered with Collaborations Pharma to use AI and Machine Learning techniques that significantly reduce development time and costs.

Israeli startups XRHealth (see previously) and CalmiGo (see previously) are donating their anxiety-relieving devices to hospitals, nursing homes, assisted living facilities and mental health centers throughout Israel. XRHealth’s headsets and CalmiGo’s inhalers help relax worried citizens.

Stanford Medicine performed the first spine surgery using the augmented reality technology from Israel’s Surgical Theater (see previously). The successful tumor resection operation employed Surgical Theater’s SyncAR Spine platform.

Israel’s MeMed (see previously) has been awarded nearly $727,800 from the US Biomedical Advanced Research and Development Authority (BARDA) to support a trial of its 15-minute MeMed BV test that distinguishes between bacterial and viral infections.

The US FDA has approved the VasQ External Vascular Support from Israel’s Laminate Medical Technologies (see previously). It follows a US 144-patients study. VasQ safely connects a patient’s arteries and veins to dialysis machines, by creating arteriovenous fistulas or AVFs.

The SmartHeart monitoring system from Israel’s SHL Telemedicine (see previously) is undergoing trials at Imperial College London. It has reduced ER visits by 27.5% and hospital readmission rates by 55%, surpassing expectations.

A trial of the PROphet blood test from Israel’s OncoHost (see previously) has proved its accuracy and reliability in predicting the best treatment for metastatic non-small cell lung cancer (NSCLC) patients. OncoHost has received orders from 29 US cancer centers since its 2023 launch.

Israel’s PhaseV develops causal machine learning (ML) technology that optimizes clinical trial design and analysis. Its goal is to prevent bio-techs wasting money on failed or badly designed trials of new treatments.  It boosts clinical trial success rates while maximizing resource and time efficiency.